{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:34:06Z","timestamp":1772555646860,"version":"3.50.1"},"reference-count":71,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei. In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite\u2013host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids.<\/jats:p>","DOI":"10.3390\/vaccines9030220","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:39:07Z","timestamp":1614904747000},"page":"220","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1811-7376","authenticated-orcid":false,"given":"Aline Maria Vasconcelos","family":"Queiroz","sequence":"first","affiliation":[{"name":"Immunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil"},{"name":"Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3100-0420","authenticated-orcid":false,"given":"Johny Wysllas de Freitas","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Immunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil"},{"name":"Postgraduate Program in Biochemistry, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6948-9823","authenticated-orcid":false,"given":"Cl\u00e1udia Jassica","family":"Moreno","sequence":"additional","affiliation":[{"name":"Immunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil"},{"name":"Postgraduate Program in Biochemistry, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8504-9636","authenticated-orcid":false,"given":"Diego M. A.","family":"Gu\u00e9rin","sequence":"additional","affiliation":[{"name":"Instituto Biofisika (CSIC-UPV\/EHU), Department of Biochemistry and Molecular Biology, University of the Basque Country, 48940 Bizkaia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1000-0149","authenticated-orcid":false,"given":"Marcelo Sousa","family":"Silva","sequence":"additional","affiliation":[{"name":"Immunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil"},{"name":"Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil"},{"name":"Postgraduate Program in Biochemistry, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil"},{"name":"Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, New University of Lisbon, 1349-008 Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"ref_1","unstructured":"DNDi\u2014Drugs for Neglected Diseases Initiative (2020, December 10). Diseases. Available online: https:\/\/dndi.org\/diseases\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","article-title":"Chagas disease","volume":"391","author":"Molina","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s00415-019-09425-7","article-title":"Update on human African trypanosomiasis (sleeping sickness)","volume":"266","author":"Kennedy","year":"2019","journal-title":"J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.18388\/abp.2014_1875","article-title":"Virus-like particles as vaccine","volume":"61","author":"Chroboczek","year":"2014","journal-title":"Acta Biochim. Pol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.vetimm.2012.04.026","article-title":"Virus-like particles: The new frontier of vaccines for animal viral infections","volume":"148","author":"Crisci","year":"2012","journal-title":"Veter Immunol. Immunopathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fimmu.2017.00226","article-title":"Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines","volume":"8","author":"Gomes","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: Passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12033-012-9598-4","article-title":"Construction and Characterization of Virus-Like Particles: A Review","volume":"53","author":"Zeltins","year":"2012","journal-title":"Mol. Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/biot.201400427","article-title":"Enveloped virus-like particles as vaccines against pathogenic arboviruses","volume":"10","author":"Pijlman","year":"2015","journal-title":"Biotechnol. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/14760584.3.2.119","article-title":"Recombivax-HB: Perspectives past, present and future","volume":"3","author":"Venters","year":"2004","journal-title":"Expert Rev. Vaccines"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0264-410X(01)00518-7","article-title":"Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: An assessment at 2 years","volume":"20","author":"Hieu","year":"2002","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1188\/06.CJON.559-560","article-title":"Gardasil\u00ae: Introducing the New Human Papillomavirus Vaccine","volume":"10","author":"McLemore","year":"2006","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1016\/j.vaccine.2008.07.002","article-title":"Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica","volume":"26","author":"Herrero","year":"2008","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Qian, C., Liu, X., Xu, Q., Wang, Z., Chen, J., Li, T., Zheng, Q., Yu, H., Gu, Y., and Li, S. (2020). Recent Progress on the Versatility of Virus-Like Particles. Vaccines, 8.","DOI":"10.3390\/vaccines8010139"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Singh, K., Marasini, B., Chen, X., Ding, L., Wang, J.-J., Xiao, P., Villinger, F., and Spearman, P. (2020). A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques. J. Virol., 94.","DOI":"10.1128\/JVI.01884-19"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/978-1-4939-3618-2_27","article-title":"Production of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect Cells","volume":"Volume 1426","author":"Metz","year":"2016","journal-title":"Chikungunya Virus: Methods and Protocols"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-018-0970-2","article-title":"Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope","volume":"15","author":"Metz","year":"2018","journal-title":"Virol. J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pillet, S., Couillard, J., Tr\u00e9panier, S., Poulin, J.-F., Yassine-Diab, B., Guy, B., Ward, B.J., and Landry, N. (2019). Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate\u2014Two randomized Phase II clinical trials in 18 to 49 and \u226550 years old adults. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216533"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1016\/j.vaccine.2019.04.042","article-title":"Parainfluenza virus 5 (PIV5) amplifying virus-like particles expressing respiratory syncytial virus (RSV) antigens protect mice against RSV infection","volume":"37","author":"Phan","year":"2019","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Boigard, H., Alimova, A., Martin, G.R., Katz, A., Gottlieb, P., and Galarza, J.M. (2017). Zika virus-like particle (VLP) based vaccine. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005608"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1016\/j.vaccine.2019.09.068","article-title":"Therapy with multi-epitope virus-like particles of B19 parvovirus reduce tumor growth and lung metastasis in an aggressive breast cancer mouse model","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"ref_24","unstructured":"World Health Organization (2021, January 05). DRAFT Landscape of COVID-19 Candidate Vaccines. Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1016\/j.vaccine.2018.08.016","article-title":"Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection","volume":"36","author":"Lee","year":"2018","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Choi, W.H., and Park, J.S. (2020). Immunogenicity and Protective Effect of a Virus-Like Particle Containing the SAG1 Antigen of Toxoplasma gondii as a Potential Vaccine Candidate for Toxoplasmosis. Biomedicines, 8.","DOI":"10.3390\/biomedicines8040091"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1016\/j.vaccine.2018.08.033","article-title":"Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults","volume":"36","author":"Chichester","year":"2018","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1038\/s41598-019-41522-5","article-title":"A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine","volume":"9","author":"Janitzek","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16833","DOI":"10.1038\/s41598-019-53208-z","article-title":"Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccine","volume":"9","author":"Williams","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_30","unstructured":"De Castro, M.C.A.B., de Albuquerque, S.D.C.G., Tavares, D.C., De Paiva-Cavalcanti, M., and Pereira, V.A. (2017). Vaccines Against Trypanosomatids. Tropical Diseases: An Overview of Major Diseases Occurring in the Americas, Betham Science Publishers. Bentham eBooks."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Michel-Tod\u00f3, L., Bigey, P., Reche, P., Pinazo, M.-J., Gasc\u00f3n, J., and Alonso-Padilla, J. (2020). Design of an Epitope-Based Vaccine Ensemble for Animal Trypanosomiasis by Computational Methods. Vaccines, 8.","DOI":"10.3390\/vaccines8010130"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/ITT.S241064","article-title":"Immunoinformatics and Vaccine Development: An Overview","volume":"9","author":"Oli","year":"2020","journal-title":"ImmunoTargets Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105168","DOI":"10.1016\/j.actatropica.2019.105168","article-title":"Immunity and vaccine development efforts against Trypanosoma cruzi","volume":"200","author":"Rios","year":"2019","journal-title":"Acta Trop."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1016\/j.vaccine.2020.05.010","article-title":"Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques","volume":"38","author":"Dumonteil","year":"2020","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"165658","DOI":"10.1016\/j.bbadis.2019.165658","article-title":"Chagas disease vaccine design: The search for an efficient Trypanosoma cruzi immune-mediated control","volume":"1866","author":"Bivona","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/DDDT.S146521","article-title":"Leishmaniasis in humans: Drug or vaccine therapy?","volume":"12","author":"Ghorbani","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_37","first-page":"21","article-title":"Recent Advances in Vaccines Against Leishmania Based on Patent Applications","volume":"11","author":"Karp","year":"2017","journal-title":"Recent Patents Biotechnol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/pim.12387","article-title":"Prospects for vaccination against pathogenic African trypanosomes","volume":"38","author":"Black","year":"2016","journal-title":"Parasite Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/molbev\/msp214","article-title":"The Evolution of Amastin Surface Glycoproteins in Trypanosomatid Parasites","volume":"27","author":"Jackson","year":"2009","journal-title":"Mol. Biol. Evol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.molbiopara.2016.03.007","article-title":"Gene family phylogeny and the evolution of parasite cell surfaces","volume":"209","author":"Jackson","year":"2016","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_41","first-page":"1","article-title":"A Brief View of the Surface Membrane Proteins fromTrypanosoma cruzi","volume":"2017","year":"2017","journal-title":"J. Parasitol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/1389202033490439","article-title":"Leishmania Cysteine Proteinases: From Gene to Subunit Vaccine","volume":"4","author":"Rafati","year":"2003","journal-title":"Curr. Genom."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.21608\/puj.2019.20020.1055","article-title":"Expression of cysteine proteinases and cystatins in parasites and use of cysteine proteinase inhibitors in parasitic diseases. Part III: Protozoa (3): Kinetoplastids","volume":"12","author":"Abaza","year":"2019","journal-title":"Parasitol. United J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.protis.2017.03.004","article-title":"In Vitro Inhibition of Leishmania Attachment to Sandfly Midguts and LL-5 Cells by Divalent Metal Chelators, Anti-gp63 and Phosphoglycans","volume":"168","author":"Soares","year":"2017","journal-title":"Protist"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Moreno, C.J.G., Torres, T., and Silva, M.S. (2019). Variable Surface Glycoprotein from Trypanosoma brucei Undergoes Cleavage by Matrix Metalloproteinases: An in silico Approach. Pathogens, 8.","DOI":"10.3390\/pathogens8040178"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1039\/D0MD00122H","article-title":"Defeating the trypanosomatid trio: Proteomics of the protozoan parasites causing neglected tropical diseases","volume":"11","author":"Parthasarathy","year":"2020","journal-title":"RSC Med. Chem."},{"key":"ref_47","first-page":"327","article-title":"Virus like particles-A recent advancement in vaccine development","volume":"55","author":"Sarkar","year":"2019","journal-title":"Korean J. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pt.2017.10.001","article-title":"The Deadly Dance of B Cells with Trypanosomatids","volume":"34","author":"Charpentier","year":"2018","journal-title":"Trends Parasitol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/eji.201847917","article-title":"Hypergammaglobulinemia sustains the development of regulatory responses during chronic Leishmania donovani infection in mice","volume":"49","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Presas, A.M., Padilla-Noriega, L., Robert, L., Jim\u00e9nez, J.A., Solano, S., Delgado, J., Tato, P., Molinari, J.L., and Becker, I. (2017). Enveloped and non-enveloped viral-like particles in Trypanosoma cruzi epimastigotes. Rev. Inst. Med. Trop. S\u00e3o Paulo, 59.","DOI":"10.1590\/s1678-9946201759046"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1021\/acscentsci.7b00311","article-title":"Virus-like Particle Display of the \u03b1-Gal Carbohydrate for Vaccination againstLeishmaniaInfection","volume":"3","author":"Moura","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Cecilio, P., P\u00e9rez-Cabezas, B., Fernandez, L., Moreno, J., Carrillo, E., Requena, J.M., Fichera, E., Reed, S.G., Coler, R.N., and Kamhawi, S. (2017). Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005951"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/14760584.6.3.381","article-title":"Virus-like particles: Flexible platforms for vaccine development","volume":"6","author":"Chackerian","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.molimm.2004.06.028","article-title":"Recombinant HIV-1 Pr55gag virus-like particles: Potent stimulators of innate and acquired immune responses","volume":"42","author":"Deml","year":"2005","journal-title":"Mol. Immunol."},{"key":"ref_55","first-page":"147","article-title":"Citocinas e \u00f3xido n\u00edtrico na Doen\u00e7a de Chagas","volume":"10","author":"Pavanelli","year":"2016","journal-title":"Biosa\u00fade"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.tim.2010.11.003","article-title":"Virus assembly, allostery and antivirals","volume":"19","author":"Zlotnick","year":"2011","journal-title":"Trends Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1016\/j.vaccine.2011.05.005","article-title":"Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins","volume":"29","author":"Visciano","year":"2011","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.33073\/pjm-2015-001","article-title":"Virus like particles as immunogens and universal nanocarriers","volume":"64","author":"Naskalska","year":"2015","journal-title":"Pol. J. Microbiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.4049\/jimmunol.178.4.2361","article-title":"Insect Baculoviruses Strongly Potentiate Adaptive Immune Responses by Inducing Type I IFN","volume":"178","author":"Rueda","year":"2007","journal-title":"J. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Balke, I., and Zeltins, A. (2020). Recent Advances in the Use of Plant Virus-Like Particles as Vaccines. Viruses, 12.","DOI":"10.3390\/v12030270"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4419-1132-2_11","article-title":"Virus-Like Particles as a Vaccine Delivery System: Myths and Facts","volume":"Volume 655","author":"Roy","year":"2009","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12275-017-7058-3","article-title":"Exploiting virus-like particles as innovative vaccines against emerging viral infections","volume":"55","author":"Jeong","year":"2017","journal-title":"J. Microbiol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Perotti, M., and Perez, L. (2019). Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV. Viruses, 12.","DOI":"10.3390\/v12010035"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.addr.2014.10.023","article-title":"Formulation and stabilization of recombinant protein based virus-like particle vaccines","volume":"93","author":"Jain","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_65","first-page":"1","article-title":"Experimental Vaccines against Chagas Disease: A Journey through History","volume":"2015","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1016\/j.vaccine.2016.03.074","article-title":"Status of vaccine research and development of vaccines for Chagas disease","volume":"34","author":"Beaumier","year":"2016","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jps.22267","article-title":"COMMENTARY: Acceptable Levels of Endotoxin in Vaccine Formulations During Preclinical Research","volume":"100","author":"Brito","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_68","unstructured":"World Health Organization (2005). WHO guidelines on nonclinical evaluation of vaccines. World Health Organ. Tech. Rep. Ser., 927, 55."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"10415","DOI":"10.1007\/s00253-015-7000-8","article-title":"The application of virus-like particles as vaccines and biological vehicles","volume":"99","author":"Yan","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41467-018-08265-9","article-title":"Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins","volume":"10","author":"Serradell","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/3\/220\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:33:09Z","timestamp":1760160789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/3\/220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":71,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["vaccines9030220"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9030220","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]}}}